Novo Nordisk's 6.4% Rebound Faces a Two-Front Audit: Brazil's Generics and America's Price Cuts
Published on 11/04/2026 at 19:10 | Editorial boerse-global.de
Novo Nordisk shares climbed 6.4% after third-quarter results and a raised full-year outlook, but the rally papers over a more awkward question. The Danish drugmaker now has to prove that its earnings surge can survive two separate pressures at once — cheaper copycat products eating into sales in Brazil, and steep US list-price reductions scheduled for January 2027.
The headline numbers were forceful. Adjusted operating profit for the third quarter of 2026 rose 27% to DKK 31.72bn, while adjusted revenue reached DKK 79.2bn, up 4% at constant exchange rates. Profit clearly outran sales, and investors should not mistake that gap for evidence of equally vigorous top-line momentum.
A Pill That Beat the Consensus
The Wegovy pill generated DKK 5.39bn in the quarter, according to Reuters — 53% more than in the prior three months and ahead of the DKK 4.62bn analyst consensus. Obesity revenue across the division rose 22% at constant currencies to DKK 26.15bn, confirming that the oral formulation is contributing real volume rather than sitting on the shelf.
Its importance becomes clearer against the injectable. US sales of the Wegovy injection fell 13% year on year at constant exchange rates in the third quarter, yet the combined US Wegovy business still grew 21%. The pill more than plugged the gap — at least in the reported period.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Novo argues the demand is genuinely new. According to a BioSpace report published today, 80% of patients who started on the Wegovy pill had previously received no treatment at all. If that pattern holds, the oral form opens an independent growth path instead of merely cannibalising the shot.
The Price Test Arrives in January
That is where the arithmetic gets harder. From January 2027, Novo plans to cut US list prices for Wegovy by roughly 50% and for Ozempic by 35%. List prices are not the same as realised revenue, so the announced reductions do not translate one-for-one into a sales decline. Still, they mean the quality of growth matters more than its headline size.
A prescription pause would sharpen the problem. Citi data show the four-week average of Wegovy pill prescriptions was essentially flat in the week to 23 October. One quiet stretch is not proof of a stall, but it limits how much weight the blockbuster quarter can carry into a period of lower prices.
Novo's own guidance already assumes regional divergence. Reuters reports that the 2026 forecast implies international revenue growth alongside a US decline. The company is not banking on a uniform upturn — and the raised outlook, spanning anything from a 2% contraction to 2% growth in both adjusted revenue and adjusted operating profit, leaves room for a downturn as well as an advance.
Brazil Shows the Patent Cliff Is Already Here
The most concrete warning comes from Latin America. Reuters reports that Novo is losing market share in Brazil following the expiry of the semaglutide patent there, with cheaper generics adding competitive pressure. That is not a hypothetical risk; one part of the business is already under strain even as group revenue rises.
Chief executive Mike Doustdar said Novo has largely held its ground in Canada and India, which argues against extrapolating the Brazilian experience to every market. It does not erase the concern. If the pressure spreads, the sales momentum that underpins today's optimism would lose force.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Two Dates on the Calendar
The next catalyst is ObesityWeek in Washington, D.C., running from 14 to 17 November, where Novo will present new data from its obesity portfolio across 26 congress contributions. These could shape views on the company's competitive position, though they are no substitute for proof of durable revenue.
Further out, the FDA is expected to rule on CagriSema before the end of 2026, with Novo planning a US launch in early 2027 subject to a positive decision. A green light would widen the product base without guaranteeing commercial success. On the leadership side, chief financial officer Karsten Munk Knudsen will step down at the end of December 2026, with Luigi La Corte slated to succeed him.
For shareholders, the yardstick stays the same regardless of who holds the finance brief: whether Novo can convert stronger GLP-1 expectations into resilient revenue while generics bite in some markets and prices fall in the largest one.
Ad
Novo Nordisk Stock: New Analysis - 4 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
